m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03496)
Name
CHR-4125
Synonyms
CHR-4146; CHR-5010; PLK-1 inhibitors (cancer), Chroma Therapeutics; Polo-like kinase-1 inhibitors (cancer); Polo-likekinase-1 inhibitors (cancer), Chroma Therapeutics
    Click to Show/Hide
Status
Investigative
TTD Drug ID
D01HHH
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Polo-like kinase 1 (PLK1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Polo-like kinase 1 (PLK1) is a therapeutic target for CHR-4125. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CHR-4125 through regulating the expression of Polo-like kinase 1 (PLK1). [1], [2]
References
Ref 1 METTL3-mediated m(6)A modification regulates cell cycle progression of dental pulp stem cells. Stem Cell Res Ther. 2021 Mar 1;12(1):159. doi: 10.1186/s13287-021-02223-x.
Ref 2 Discovery of thiophene inhibitors of polo-like kinase. Bioorg Med Chem Lett. 2009 Feb 1;19(3):1018-21. doi: 10.1016/j.bmcl.2008.11.041. Epub 2008 Nov 18.